Acerus Announces Resignation of Director

TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Company ContactNaveed ManzoorChief Financial Officer[email protected]

Source: Acerus Pharmaceuticals Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JBS Reports Second Quarter 2026 Results
• Finning Announces Pricing of $300 Million of 4.231% Senior Unsecured Notes
• Diana Shipping Inc. and Star Bulk Carriers Announce Mutual Agreement to Terminate Vessel Sale and Purchase Agreement